Kythera appoints Elisabeth Sandoval CCO
This article was originally published in Scrip
Kythera Biopharmaceuticals, a privately-held biotech developing prescription products in aesthetic medicine, has named Elisabeth Sandoval chief commercial officer. Ms Sandoval has over 25 years' experience of the pharmaceutical and medical device industries, having spent 20 years at Allergan. She joins Kythera from Bausch + Lomb Surgical, where she most recently served as vice-president of global marketing & strategy.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.